Sebia Inc. Hydrasys 2 Reagents for the Department of Laboratory Medicine
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
|---|---|
| State: | Maryland |
| Type of Government: | Federal |
| FSC Category: |
|
| NAICS Category: |
|
| Posted Date: | Jan 17, 2025 |
| Due Date: | Jan 31, 2025 |
| Solicitation No: | 25-001509 |
| Original Source: | Please Login to View Page |
| Contact information: | Please Login to View Page |
| Bid Documents: | Please Login to View Page |
Description
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Presolicitation (Updated)
- Updated Published Date: Jan 17, 2025 04:26 pm EST
- Original Published Date: Jan 17, 2025 04:26 pm EST
- Updated Response Date: Jan 31, 2025 06:30 am EST
- Original Response Date: Jan 31, 2025 06:30 am EST
- Inactive Policy: Manual
- Updated Inactive Date: Feb 01, 2025
- Original Inactive Date: Feb 01, 2025
-
Initiative:
- None
- Original Set Aside:
- Product Service Code: 6550 - IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS
-
NAICS Code:
- 325413 - In-Vitro Diagnostic Substance Manufacturing
-
Place of Performance:
Bethesda , MD 20892USA
Title
Sebia Inc. Hydrasys 2 Reagents for the Department of Laboratory Medicine
- Product Service Code: 6550
- NAICS Code: 325413
- Place of Performance:
Bethesda, MD 20892 USA
POTS: 25-001509
Description
This is a notice of intent, NOT a request for a quotation. A solicitation document will NOT be issued, and quotations will NOT be requested.
The National Institutes of Health (NIH) plans to issue a fixed-price purchase order on a sole-source basis to Sebia Inc., located in Norcross, Georgia (ZIP code: 30093-2991). The order will include a base year, followed by four 12-month option years. The period of performance will run from March 15, 2025, to March 14, 2030.
The purpose of this acquisition is to procure Sebia reagent kits, quality control materials, and supplies necessary to continue electrophoresis testing for patient care within the Chemistry Service of the Department of Laboratory Medicine.
Sebia Hydrasys B1/B2 reagent kits are designed for the separation and quantification of proteins in human serum and urine using agarose gel electrophoresis. These kits offer enhanced resolution and sensitivity, particularly for detecting monoclonal bands. The Sebia Hydrasys IF reagent kits are intended for the detection and identification of monoclonal proteins through immunofixation electrophoresis. Both the B1/B2 and IF kits play a crucial role in monitoring patients with B-cell malignancies, such as Multiple Myeloma and Chronic Lymphocytic Leukemia, who are undergoing treatment at Clinical Centers.
Additionally, the Hydrasys Isofocusing reagent kits enable qualitative detection and identification of oligoclonal bands in electrophoretic patterns from cerebrospinal fluid. These kits are specifically used for monitoring central nervous system diseases in Clinical Center patients.
The Sebia reagent kits are specifically designed for compatibility with the Sebia Hydrasys 2 analyzers, which are currently located in and utilized by the Department of Laboratory Medicine.
**** See the attached list of items that must be provided with this order *****
Sebia Inc. is the exclusive manufacturer, vendor, and service provider for the Hydrasys 2 electrophoresis system. The product design is unique, proprietary, and cannot be sourced from any other vendors.
This acquisition is being conducted using policies unique to the Federal Acquisition Regulation 13.501 Special documentation requirements for sole source acquisitions exceeding the Simplified Acquisition Threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.
Interested parties may identify their interest and submit capability statements in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.
Comments to this announcement, referencing this posting number, may be submitted to the Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Shasheshe Goolsby, Lead Contract Specialist, shasheshe.goolsby@nih.gov by January 31, 6:30AM EST.
*** Please send your capability statements ONLY. This IS NOT a request for quotation. ***
- 6707 DEMOCRACY BLVD, SUITE 106
- BETHESDA , MD 20892
- USA
- Shasheshe Goolsby
- shasheshe.goolsby@nih.gov
- Phone Number 3018274879
- Jan 17, 2025 04:26 pm ESTPresolicitation (Updated)
- Jan 17, 2025 04:26 pm EST Presolicitation (Original)
Related Document
| Mar 25, 2025 | [Presolicitation (Updated)] Sebia Inc. Hydrasys 2 Reagents for the Department of Laboratory Medicine |
See Also
Follow Single cell methylation Active Contract Opportunity Notice ID 75N98026Q01085 Related Notice Department/Ind.
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Due by 9/20/2026
Follow Specialized Blood Products-AABB Active Contract Opportunity Notice ID 26-008618 Related Notice Department/Ind.
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Due by 9/20/2026
Follow Electrosurgical unit (ESU) Active Contract Opportunity Notice ID 75F40126Q00277 Related Notice Department/Ind.
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Due by 9/16/2026
Follow NOTICE OF INTENT TO SOLE SOURCE - PROCUREMENT OF THE BIO-RAD CHEMIDOC
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Due by 9/18/2026